Oren Gilad - Oct 10, 2024 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
President/CEO, Director
Signature
/s/ John Hamill, as Attorney-in-Fact
Stock symbol
APRE
Transactions as of
Oct 10, 2024
Transactions value $
$2,971
Form type
4
Date filed
10/15/2024, 08:31 AM
Previous filing
Mar 28, 2024
Next filing
Oct 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Purchase $381 +150 +0.05% $2.54 332K Oct 10, 2024 Direct
transaction APRE Common Stock Purchase $2.59K +1K +0.3% $2.59 333K Oct 14, 2024 Direct
holding APRE Common Stock 1.2K Oct 10, 2024 By Daughter F1
holding APRE Common Stock 600 Oct 10, 2024 By Son F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.